Testicular cancer
A patient’s testicular germ cell tumors determine the sort of testicular cancer they develop. The studies indicate that approximately 28% of testicular cancer patients have both seminomas and non-seminomas, with 55% of the seminomas and 13% of the non-seminomas. Almost every treatment for testicular cancer begins with surgical procedures to remove the tumor, followed by chemotherapy to prevent the spread of cancer cells. 71% of stage 1 seminomas are treated with surgery alone, whereas 67% of stage 3 seminomas are treated with chemotherapy in addition to surgery. In addition, 60% of stage 2 seminomas are treated with surgery and chemotherapy. After chemotherapy, the prognosis for mixed cases is 94%, for non-seminomas it is 90%, and for seminomas it is 99%.
57% of patients with non-seminosmatous testicular germ cells at stage 1 are only offered surgery, and 50% of non-seminosmatous patients at stage 2 receive chemotherapy in addition to surgery. The remaining 31% of non-seminosmatous patients are advised by oncologists to undergo a combination of retroperitoneal lymph node dissection and chemotherapy. 56% of stage 3 non-seminoma patients receive only chemotherapy and surgery, while 18% receive retroperitoneal lymph node dissection and chemotherapy and 19% receive radiation and chemotherapy. The overall survival rate following chemotherapy treatment for testicular cancer is 99 percent.
